Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.75
MDCO's Cash to Debt is ranked lower than
69% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. MDCO: 0.75 )
Ranked among companies with meaningful Cash to Debt only.
MDCO' s Cash to Debt Range Over the Past 10 Years
Min: 0.64  Med: 10000.00 Max: No Debt
Current: 0.75
Equity to Asset 0.41
MDCO's Equity to Asset is ranked lower than
78% of the 697 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MDCO: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
MDCO' s Equity to Asset Range Over the Past 10 Years
Min: 0.41  Med: 0.77 Max: 0.89
Current: 0.41
0.41
0.89
F-Score: 2
Z-Score: 0.80
M-Score: -3.71
WACC vs ROIC
2.68%
-31.81%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -146.93
MDCO's Operating margin (%) is ranked lower than
89% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.49 vs. MDCO: -146.93 )
Ranked among companies with meaningful Operating margin (%) only.
MDCO' s Operating margin (%) Range Over the Past 10 Years
Min: -88.18  Med: -0.60 Max: 14.87
Current: -146.93
-88.18
14.87
Net-margin (%) -193.40
MDCO's Net-margin (%) is ranked lower than
91% of the 706 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.03 vs. MDCO: -193.40 )
Ranked among companies with meaningful Net-margin (%) only.
MDCO' s Net-margin (%) Range Over the Past 10 Years
Min: -114.16  Med: -0.09 Max: 29.79
Current: -193.4
-114.16
29.79
ROE (%) -52.67
MDCO's ROE (%) is ranked lower than
88% of the 732 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. MDCO: -52.67 )
Ranked among companies with meaningful ROE (%) only.
MDCO' s ROE (%) Range Over the Past 10 Years
Min: -42.69  Med: -0.43 Max: 35
Current: -52.67
-42.69
35
ROA (%) -22.89
MDCO's ROA (%) is ranked lower than
83% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.72 vs. MDCO: -22.89 )
Ranked among companies with meaningful ROA (%) only.
MDCO' s ROA (%) Range Over the Past 10 Years
Min: -20  Med: -0.32 Max: 24.65
Current: -22.89
-20
24.65
ROC (Joel Greenblatt) (%) -430.30
MDCO's ROC (Joel Greenblatt) (%) is ranked lower than
88% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.14 vs. MDCO: -430.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MDCO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -168.9  Med: -4.82 Max: 300.56
Current: -430.3
-168.9
300.56
Revenue Growth (3Y)(%) -22.90
MDCO's Revenue Growth (3Y)(%) is ranked lower than
90% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. MDCO: -22.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MDCO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 9.90 Max: 88.5
Current: -22.9
0
88.5
» MDCO's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-29)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

MDCO Guru Trades in Q2 2015

RS Investment Management 367,318 sh (+8.56%)
Vanguard Health Care Fund 5,564,220 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Chuck Royce 202,932 sh (-90.25%)
» More
Q3 2015

MDCO Guru Trades in Q3 2015

Jim Simons 96,432 sh (New)
RS Investment Management 680,692 sh (+85.31%)
Vanguard Health Care Fund 5,564,220 sh (unchged)
Chuck Royce 137,932 sh (-32.03%)
» More
Q4 2015

MDCO Guru Trades in Q4 2015

Steven Cohen 656,500 sh (New)
Jim Simons 249,032 sh (+158.25%)
RS Investment Management 1,198,632 sh (+76.09%)
Vanguard Health Care Fund 5,564,220 sh (unchged)
Chuck Royce 108,232 sh (-21.53%)
» More
Q1 2016

MDCO Guru Trades in Q1 2016

Jim Simons 287,361 sh (+15.39%)
RS Investment Management 1,307,762 sh (+9.10%)
Vanguard Health Care Fund 5,564,220 sh (unchged)
Steven Cohen 319,700 sh (-51.30%)
Chuck Royce 50,232 sh (-53.59%)
» More
» Details

Insider Trades

Latest Guru Trades with MDCO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:XTER:SAZ, NAS:ENDP, TSE:4516, SZSE:000028, SZSE:000999, SZSE:000623 » details
Traded in other countries:MZN.Germany,
The Medicines Co is a biopharmaceutical company. The Company markets Angiomax, Cleviprex injectable emulsion, Minocin for injection, Orbactiv, PreveLeakTM and Recothrom Thrombin topical. The Company also sells ready‑to‑use formulation of Argatroban.

The Medicines Co was incorporated in Delaware on July 31, 1996. The Company is a global biopharmaceutical company focused on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on 3,000 acute and intensive care hospitals worldwide. The Company markets products including; Angiomax (bivalirudin), Recothrom Thrombin, topical (Recombinant), Cleviprex (clevidipine) injectable emulsion and Minocin IV (Minocycline for Injection). Angiomax is an intravenous direct thrombin inhibitor that is a peptide compound. Recothrom is a surgical hemostat that is applied topically during surgery to stop bleeding. Cleviprex is an intravenous small molecule calcium channel blocker. Minocin IV is an Tetracycline-class antibiotic used for treatment of bacterial infections caused by Acinetobacter species. The Company has a pipeline of acute and intensive care hospital products in development, including five registration stage product candidates; cangrelor, oritavancin, IONSYSTM (fentanyl iontophoretic transdermal system), Fibrocaps and RPX-602, and three research and development product candidates, MDCO-216, CarbavanceTM and ALN-PCSsc. In addition to these products and product candidates company also sells a ready-to-use formulation of Argatroban and have a portfolio of ten generic drugs, referred to as acute care generic products, that have the non-exclusive right to market in the United States. The Company is currently selling three of its acute care generic products, midazolam, ondansetron and rocuronium; and also co-promote the oral tablet antiplatelet medicine BRILINTA (ticagrelor) in the United States as part of global collaboration agreement with AstraZeneca LP and the Boston Scientific Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, or the Promus PREMIER Stent System, in the United States under its co-promotion agreement with Boston Scientific Corporation, or BSX. It faces competition from pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. The Company and its customers are subject to extensive regulation by the federal government, and the governments of the states and foreign countries in which it may conduct its business. In addition to regulations in the United States, the Company is subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of its products.

Ratios

vs
industry
vs
history
P/B 4.08
MDCO's P/B is ranked lower than
66% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. MDCO: 4.08 )
Ranked among companies with meaningful P/B only.
MDCO' s P/B Range Over the Past 10 Years
Min: 1.14  Med: 2.50 Max: 6.94
Current: 4.08
1.14
6.94
P/S 10.85
MDCO's P/S is ranked lower than
83% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.72 vs. MDCO: 10.85 )
Ranked among companies with meaningful P/S only.
MDCO' s P/S Range Over the Past 10 Years
Min: 0.9  Med: 2.90 Max: 10.85
Current: 10.85
0.9
10.85
Current Ratio 1.31
MDCO's Current Ratio is ranked lower than
79% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. MDCO: 1.31 )
Ranked among companies with meaningful Current Ratio only.
MDCO' s Current Ratio Range Over the Past 10 Years
Min: 0.75  Med: 4.05 Max: 10.09
Current: 1.31
0.75
10.09
Quick Ratio 1.15
MDCO's Quick Ratio is ranked lower than
70% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. MDCO: 1.15 )
Ranked among companies with meaningful Quick Ratio only.
MDCO' s Quick Ratio Range Over the Past 10 Years
Min: 0.75  Med: 3.56 Max: 9.44
Current: 1.15
0.75
9.44
Days Inventory 349.39
MDCO's Days Inventory is ranked lower than
95% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.44 vs. MDCO: 349.39 )
Ranked among companies with meaningful Days Inventory only.
MDCO' s Days Inventory Range Over the Past 10 Years
Min: 72.24  Med: 119.28 Max: 315.65
Current: 349.39
72.24
315.65
Days Sales Outstanding 67.16
MDCO's Days Sales Outstanding is ranked higher than
56% of the 613 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.15 vs. MDCO: 67.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDCO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.9  Med: 46.36 Max: 78.45
Current: 67.16
26.9
78.45
Days Payable 53.98
MDCO's Days Payable is ranked lower than
65% of the 584 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.00 vs. MDCO: 53.98 )
Ranked among companies with meaningful Days Payable only.
MDCO' s Days Payable Range Over the Past 10 Years
Min: 15.33  Med: 44.81 Max: 109.68
Current: 53.98
15.33
109.68

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 5.63
MDCO's Price/Projected FCF is ranked lower than
70% of the 304 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.58 vs. MDCO: 5.63 )
Ranked among companies with meaningful Price/Projected FCF only.
MDCO' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.84  Med: 1.60 Max: 11.15
Current: 5.63
0.84
11.15
Price/Median PS Value 3.74
MDCO's Price/Median PS Value is ranked lower than
93% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.12 vs. MDCO: 3.74 )
Ranked among companies with meaningful Price/Median PS Value only.
MDCO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.33  Med: 1.30 Max: 61.83
Current: 3.74
0.33
61.83
Earnings Yield (Greenblatt) (%) -11.30
MDCO's Earnings Yield (Greenblatt) (%) is ranked lower than
85% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. MDCO: -11.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDCO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -11.3  Med: 4.20 Max: 15.2
Current: -11.3
-11.3
15.2
Forward Rate of Return (Yacktman) (%) -7.35
MDCO's Forward Rate of Return (Yacktman) (%) is ranked lower than
77% of the 323 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.27 vs. MDCO: -7.35 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MDCO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -16.6  Med: 1.90 Max: 5.2
Current: -7.35
-16.6
5.2

More Statistics

Revenue (TTM) (Mil) $232.8
EPS (TTM) $ -6.61
Beta0.01
Short Percentage of Float35.40%
52-Week Range $25.38 - 43.79
Shares Outstanding (Mil)70.07

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 202 252 472
EPS ($) -2.38 -2.52 -0.79
EPS without NRI ($) -2.38 -2.52 -0.79
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for MDCO

Headlines

Articles On GuruFocus.com
Netflix Profit Above Consensus, Panera Bread Boosts Buyback Plan, Medicines Co Cangrelor Well-Recomm Apr 16 2015 
Chuck Royce Buys Stifel Financial, Tidewater, Alamos, Sells Kennametal, Gardner Denver, Gartner Apr 25 2013 
Weekly CFO Sells Highlight: BK, MDCO, EBAY, MS, PHMD Jan 27 2013 
Weekly CFO Sells Highlight: MDCO, SIG, VCI, PHMD, SNPS Jan 21 2013 
George Soros' Top Buys in the Last Quarter Dec 23 2011 
George Soros Buys Amazon.com Inc., Motorola Solutions, Sandisk, Sells Ralph Lauren, Dendreon, Lawson Nov 15 2011 
Medicines Company (MDCO) Chairman & CEO Clive Meanwell sells 100,000 Shares Mar 01 2011 
Medicines Company Reports Operating Results (10-Q) Nov 09 2010 
Medicines Company Reports Operating Results (10-Q) May 10 2010 
Medicines Company (MDCO) Chairman & CEO Clive Meanwell sells 181,500 Shares May 04 2010 

More From Other Websites
New incentives needed to develop antibiotics to fight superbugs May 29 2016
New incentives needed to develop antibiotics to fight superbugs May 27 2016
New incentives needed to develop antibiotics to fight superbugs May 27 2016
The Medicines Co. Carbavance TANGO 1 Study Enrolled May 27 2016
The Medicines Company Announces Completion of Patient Enrollment in Phase 3 TANGO 1 Study of... May 26 2016
The Medicines Company Announces Completion of Patient Enrollment in Phase 3 TANGO 1 Study of... May 26 2016
The Medicines Company to Present at Two Upcoming Investor Conferences May 25 2016
The Medicines Company to Present at Two Upcoming Investor Conferences May 25 2016
Valeant Pharmaceuticals: It's Complicated May 24 2016
MEDICINES CO /DE Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... May 18 2016
MEDICINES CO /DE Financials May 18 2016
The Medicines Company Appoints Tony Kingsley as President and Chief Operating Officer May 16 2016
The Medicines Company Appoints Tony Kingsley as President and Chief Operating Officer May 16 2016
MEDICINES CO /DE Files SEC form 8-K, Entry into a Material Definitive Agreement, Costs Associated... May 13 2016
The Medicines Co. breached its 50 day moving average in a Bearish Manner : MDCO-US : May 12, 2016 May 12 2016
The Medicines Co. Loss Wider, to Divest Cardiovascular Drugs May 10 2016
The Medicines Co. :MDCO-US: Earnings Analysis: Q1, 2016 By the Numbers May 10 2016
Edited Transcript of MDCO earnings conference call or presentation 9-May-16 12:30pm GMT May 09 2016
Deals of the day- Mergers and acquisitions May 09 2016
Medicines Co to sell cardiovascular drugs to Italy's Chiesi May 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)